Market Report -- In Play (CYTK)

November 19, 2009 7:32 AM ET

Article tools

Stocks mentioned in this article: Cytokinetics Inc (CYTK) Stock Quote, Chart, News, Add to Watchlist
Related topics: Movers

Cytokinetics announces non-clinical data relating to GSK-923295 presented at the 2009 AACR-NCI-EORTC International Conference Co announces that abstracts summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held November 15-19, 2009 in Boston, Massachusetts. A poster titled "Synergistic Interaction Between CENP-E inhibitor GSK923295 and MEK inhibitor GSK1120212" was presented by Yan Y. Degenhardt, Ph.D., GlaxoSmithKline on Tuesday, November 17, 2009. This poster presentation summarized a non-clinical study evaluating the combination of the CENP-E inhibitor, GSK-923295, and a MEK inhibitor, GSK-1120212, to determine if this combination might improve clinical efficacy over either compound as a single agent in selected tumors. This study identified multiple genes along the MAPK pathway as hits in a synthetic lethal siRNA library screen for GSK-923295, suggesting that inhibiting the MAPK pathway may enhance sensitivity of cells to GSK-923295. The combination of these two drug candidates was tested by fixed-ratio dosing in 5 colon cell lines, 15 lung cell lines and 8 pancreas lines. Synergy between these two drug candidates was observed in most of the cell lines using one or more judging criteria; there was no association with genetic background. Finally, as measured by caspase assay, more apoptosis was induced in the presence of both drugs than either alone.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.